Convertible Notes Corporate Debt Equity Financing Investment Strategies Loans Credit Facilities Capital Raising Public Debt Bridge Loans Convertible Debt Short-term Debt High-Yield Bonds Investment Firms Loan Agreements Interest Rates Bond Issuance Corporate Strategy Non-Convertible Debentures Tech Companies Bid Conditions Acquisition Funding Syndicated Loans Funding Rounds Bondholders Initial Public Offerings Municipal Borrowing Sector Investments Curefoods Non-Dilutive Debt Sovereign Debt Credit Ratings Mortgage Lending International Investments Credit Lines Corporate Financing Leveraged Buyouts JPMorgan Startup Financing Funding Commitments Trade Financing Creditors Structured Finance Lease Financing Senior Debt Facility Special Purpose Vehicles Cash Flow Management Debt Commitments AI Investments Funding Strategies Capital Markets Financial Advisors State Financial Management Corporate Partnerships Banking Institutions Marketplace Exchange Offer Transaction Structure Corporate Bonds Credit Agreements Loan Facilities Stock Dilution Asset-Based Lending Market Trends Asset Management Investment Synopsys Debt Financing Leveraged Loans Debt Investors Investment Partnerships Debt Reduction Equity Rollover Bonds External Debt Facilities
The debt-funded purchase adds late-stage URAT1 inhibitor pozdeutinurad with 2026 Phase 3 results expected to guide filings.